Exploration of alginates as potential stabilizers of nanosuspension

The objective of this study was to explore the feasibility of using alginate as a potential stabilizer of nanosuspension and elaborate the corresponding stabilization mechanism. Using lovastatin as a Biopharmaceutics Classification System (BCS) II drug model, alginate-stabilized nanosuspension was fabricated by the high-pressure homogenization method. The particle size, zeta potential, short-term stability, and dissolution behavior of the nanosuspension were characterized. Thereafter, the surface morphology, crystallinity, redispersability, and stability of the spray-dried nanosuspension were investigated. The spray-dried powder was further compressed into tablets via direct compression, and stressing test was carried out to investigate the stability of nanocrystal loaded tablets. It was demonstrated that alginate could stabilize nanocrystals by providing both electrostatic and steric stabilization, and the effective concentration was much lower than that of the commonly used stabilizers. Good redispersability was achieved after spray drying of the nanosuspension, and the existing state of lovastatin was not changed as indicated by X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) studies. The stress test indicated that nanocrystal-loaded tablets possessed a favorable stability. In conclusion, alginate could be used as a potential stabilizer of nanosuspension with preferable stabilizing ability at a very low concentration either in liquid or in solid state.

[1]  Ranjita Shegokar,et al.  Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. , 2010, International journal of pharmaceutics.

[2]  Rainer H Müller,et al.  Development of an oral rutin nanocrystal formulation. , 2009, International journal of pharmaceutics.

[3]  Shirui Mao,et al.  Drug release characteristics from chitosan-alginate matrix tablets based on the theory of self-assembled film. , 2013, International journal of pharmaceutics.

[4]  V. Junyaprasert,et al.  Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs , 2015 .

[5]  Barrett E. Rabinow,et al.  Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.

[6]  Rainer H Müller,et al.  Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  Shirui Mao,et al.  Effect of novel stabilizers--cationic polymers on the particle size and physical stability of poorly soluble drug nanocrystals. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[8]  W. Higuchi,et al.  Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. , 1970, Journal of pharmaceutical sciences.

[9]  R. Prud’homme,et al.  Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. , 2011, International journal of pharmaceutics.

[10]  Patrick Augustijns,et al.  Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. , 2008, International journal of pharmaceutics.

[11]  Jagannath Sahoo,et al.  Formulation and process optimization of naproxen nanosuspensions stabilized by hydroxy propyl methyl cellulose. , 2015, Carbohydrate polymers.

[12]  F. Martin,et al.  Phospholipids and Lipid-Based Formulations in Oral Drug Delivery , 2010, Pharmaceutical Research.

[13]  C. Lipinski Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[14]  Jinming Gao,et al.  Nanonization strategies for poorly water-soluble drugs. , 2011, Drug discovery today.

[15]  Xin Zhang,et al.  Preparation and solidification of redispersible nanosuspensions. , 2014, Journal of pharmaceutical sciences.

[16]  G. Dudarenko,et al.  Change of molecular weight distribution of polymers by adsorption from binary and ternary solutions , 2008 .

[17]  R. Müller,et al.  Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.

[18]  Jan Van Humbeeck,et al.  Downscaling Drug Nanosuspension Production: Processing Aspects and Physicochemical Characterization , 2009, AAPS PharmSciTech.

[19]  A. Sallam,et al.  Evaluation of Tadalafil Nanosuspensions and Their PEG Solid Dispersion Matrices for Enhancing Its Dissolution Properties , 2014, AAPS PharmSciTech.

[20]  Ying Zheng,et al.  Stability of nanosuspensions in drug delivery. , 2013, Journal of Controlled Release.

[21]  K. Kohli,et al.  Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. , 2010, Drug discovery today.

[22]  Jonghwi Lee,et al.  Effect of polymer molecular weight on nanocomminution of poorly soluble drug. , 2008, Drug Delivery.

[23]  O. Smidsrod Solution properties of alginate , 1970 .

[24]  Diane J Burgess,et al.  A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. , 2009, International journal of pharmaceutics.

[25]  Wei Sun,et al.  Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption. , 2011, Journal of pharmaceutical sciences.

[26]  A. D'emanuele,et al.  In situ gelling xyloglucan/alginate liquid formulation for oral sustained drug delivery to dysphagic patients , 2009, Drug development and industrial pharmacy.

[27]  S. Benita,et al.  Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.